In a systematic review encompassing 157 RDEB–cSCC cases, only a handful were treated with PD 1 inhibitors—cemiplimab (8 cases), nivolumab (1 case), and pembrolizumab (2 cases). This evidence concerns the gene RPL17 and skin squamous cell carcinoma.